News
BIOR
0.7230
-2.35%
-0.0174
BIORA THERAPEUTICS TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE
Reuters · 1d ago
Weekly Report: what happened at BIOR last week (0429-0503)?
Weekly Report · 2d ago
Biora Therapeutics To Present Clinical Data On Device Function Of The NaviCap Oral Delivery Platform At Digestive Disease Week 2024
Biora Therapeutics will present clinical data on device function of the NaviCap™ Targeted Oral Delivery Platform at Digestive Disease Week. The meeting will take place May 18-21, 2024 in Washington, DC. Biora is a biotech company that is reimagining therapeutic delivery.
Benzinga · 2d ago
Biora Therapeutics Announces Completion Of Multiple-Ascending Dose Cohorts For Clinical Trial Of BT-600
Dosing of all patients in the trial has been successfully completed. Final results are expected to be available in late Q2 2024. BT-600 is being developed for the potential treatment of patients with ulcerative colitis. Biora's NaviCap device delivers a proprietary liquid formulation of tofacitinib to the colon.
Benzinga · 04/30 12:07
BIORA THERAPEUTICS INC - FINAL RESULTS ARE EXPECTED TO BE AVAILABLE IN LATE Q2 2024
Reuters · 04/30 12:00
Weekly Report: what happened at BIOR last week (0422-0426)?
Weekly Report · 04/29 12:34
Weekly Report: what happened at BIOR last week (0415-0419)?
Weekly Report · 04/22 12:16
12 Health Care Stocks Moving In Thursday's After-Market Session
Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. Biora Therapeutics, Mustang Bio and China SXT Pharmaceuticals were among the top gainers. Virpax Pharmaceuticals stock decreased by 18.2% during the session.
Benzinga · 04/18 20:31
Weekly Report: what happened at BIOR last week (0408-0412)?
Weekly Report · 04/15 12:06
Biora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery Innovations
TipRanks · 04/09 10:17
BIORA THERAPEUTICS, INC <BIOR.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $15 FROM $50
Reuters · 04/09 10:05
Biora Therapeutics files to sell 10.7M common shares for holders
Healthcare Biora Therapeutics files to sell 10.7M common shares for holders. The company filed a prospectus related to the proposed resale of 10. 7M common Shares. Bior a Therapeutic, Inc. (BIOR) Stock.
Seeking Alpha · 04/08 20:26
BIORA THERAPEUTICS- FILES PROSPECTUS RELATES TO OFFER & RESALE FROM TIME TO TIME BY SELLING STOCKHOLDER OF UP TO 10.7 MLN SHARES OF COMMON STOCK
Reuters · 04/08 20:11
Weekly Report: what happened at BIOR last week (0401-0405)?
Weekly Report · 04/08 12:12
Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Biora Therapeutics, Inc. Announces the issuance of a new patent related to the company's BioJet platform for oral, systemic delivery of biotherapeutics. The company uses an ingestible device to achieve systemic uptake through liquid jet delivery to the small intestine. Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform.
Benzinga · 04/08 12:02
Biora Therapeutics reports positive results from its clinical trial of BT-600
Healthcare Biora Therapeutics reports positive results from its clinical trial of BT-600. All pharmacokinetic endpoints were met in all study participants. The drug was well tolerated with no serious adverse events, according to the interim results. Bior a Therapeutic, Inc. (BIOR) is a biopharmaceutical company.
Seeking Alpha · 04/04 12:55
Biora Therapeutics Achieves Interim Results For Clinical Trial Of BT-600, Advancing NaviCap Platform Development
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no safety signals observed Multiple-ascending dose (MAD) portion of the trial is underway and progressing well. Biora is developing BT-600 for the potential treatment of ulcerative colitis.
Benzinga · 04/04 12:04
BIORA THERAPEUTICS INC - FINAL RESULTS ARE EXPECTED TO BE AVAILABLE IN LATE Q2 2024
Reuters · 04/04 12:00
Press Release: Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Announces Closing of $6 million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules. Biora is a biotech company that is reimagining therapeutic delivery. The gross proceeds of the offering of shares were approximately $6,000,000. The company intends to use the proceeds to support its operations.
Dow Jones · 04/03 20:05
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Nuvve Holding Corp. (NASDAQ:NVVE) fell sharply after the company reported worse-than-expected fourth-quarter financial results. The company posted a quarterly loss of $6.98 per share. Vast Renewables Limited shares jumped 179% to $8.62 after jumping 39% on Thursday.
Benzinga · 04/01 18:31
More
Webull provides a variety of real-time BIOR stock news. You can receive the latest news about BIORA THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About BIOR
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.